WCN26-6458 UNDERSTANDING THE IMPLEMENTATION OF SICK DAY MEDICATION GUIDANCE BY HEALTH CARE PROFESSIONALS: A SURVEY EVALUATION

Read full text Summarise with VIRAT
Authors: Mimi Truong, Kamal Sud, Connie Van, Ronald Lynel Castelino
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Development of acute kidney injury (AKI) in the community is associated with hospitalisations, risk of progression to chronic kidney disease (CKD) and patient mortality. Certain medications increase the risk of AKI during acute illness, including sulfonylureas, angiotensin converting enzyme inhibitors (ACEi), diuretics, metformin, angiotensin receptor blockers (ARBs), non-steroidal anti-inflammatories drugs (NSAIDS), and sodium glucose co-transporter 2 (SGLT2) inhibitors (SADMANS medications). The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD recommends temporary cessation of these medications through sick day medication guidance (SDMG).

Fields of Study & Subjects

Acute Kidney Injury Research Pharmaceutical Practices and Patient Outcomes Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105694–105694
Publication date
25 March 2026
Language
EN